In contrast to the thoroughly characterized mechanisms of positive regulation within cytokine signaling pathways, our knowledge of negative feedback loops is comparatively sparse. We and others have previously reported that IRAK-M down-regulates inflammatory responses to multiple stimuli. In particular, we could show that the nitric oxide (NO) donor, GSNO, induces IRAK-M overexpression in human monocytes. Here we study the expression of another important negative regulator of cytokine signaling, SOCS-1, in human monocytes exposed to GSNO. The NO donor induced significant levels of SOCS-1 mRNA and protein, 6 h and 16 h after stimulation, respectively. Monocytes stimulated with GSNO for longer periods (24 h and 48 h) failed to express IL-6 and IP-10 upon LPS challenge. In addition, and in line with previous reports of NO-mediated induction of TNF-α, we have found that exposure to this cytokine induces SOCS-1 mRNA in human monocytes. A blocking antibody against TNF-α impaired SOCS-1 expression upon GSNO treatment and re-instated IL-6 and IP-10 mRNA levels after LPS challenge in cultures pretreated with the NO donor. We conclude that NO stimulates SOCS-1 overexpression in a pathway at least partially regulated by TNF-α.
Moncada S.Nitric oxide: discovery and impact on clinical medicine. J R Soc Med1999; 92: 164—169.
2.
Chen T., Zamora R., Zuckerbraun B., Billiar TRRole of nitric oxide in liver injury. CurrMol Med2003; 3: 519—526.
3.
Brennan PA, Moncada S.From pollutant gas to biological messenger: the diverse actions of nitric oxide in cancer. Annu Rev CollSurg2002; 84: 75—78.
4.
Zeidler MR, Kleerup EC, Tashkin DPExhaled nitric oxide in the assessment of asthma. Curr Opin Pulmon Med2004; 10: 31—36.
5.
Guzik TJ, Korbut R., Adamek-Guzik T.Nitric oxide and superoxide in inflammation and immune regulation. J Physiol Pharmacol2003; 54: 469—487.
6.
Boje KMNitric oxide neurotoxicity in neurodegenerative diseases. Front Biosci2004; 9: 763—776.
7.
Zucker IH, Schultz HD, Li YF, Wang Y., Wang W., Patel KPThe origin of sympathetic outflow in heart failure: the roles of angiotensin II and nitric oxide. Prog Biophys Mol Biol2004; 84: 217—232.
8.
Okuno T., Nakatsuji Y., Kumanogoh A. et al. Loss of dopaminergic neurons by the induction of inducible nitric oxide synthase and cyclooxygenase-2 via CD40: relevance to Parkinson's disease . J Neurosci Res2005; 86: 874—872.
9.
James S.Role of nitric oxide in parasitic infections. Microb. Ref.1995; 59: 533—547
Scharton-Kersten TM, Yap G., Magram J., Sher A.Inducible nitric oxide is essential for host control of persistent but not acute infection with the intracellular pathogen Toxoplasma gondii. J Exp Med1997; 185: 1261—1273.
12.
Giacomodonato MN, Goren NB, Sordelli DO et al. Involvement of intestinal inducible nitric oxide synthase (iNOS) in the early stages of murine salmonellosis. FEMS Microbiol Lett2003; 223: 231—238.
13.
Cantoni L., Di Nicolantonio F., Barelli D., Rizzardini M., De Matteis F.Modulation of cerebellar and hepatic nitric oxide synthase by exogenous arginine and endotoxin. Nitric Oxide2001; 5: 198—207.
14.
Suschek CV, Schnorr O., Kolb-Bachofen V.The role of iNOS in chronic inflammatory processes in vivo: is it damage-promoting, protective, or active at all? CurrMol Med2004; 4: 763—775.
15.
Salzman AL, Eaves-Pyles T., Linn SC, Denenberg AG, Szabo C.Bacterial induction of inducible nitric oxide synthase in cultured human intestinal epithelial cells. Gastroenterology1998; 114: 93—102.
16.
Salzman A., Denenberg AG, Ueta I., O'Connor M., Linn SC, Szabo C.Induction and activity of nitric oxide synthase in cultured human intestinal epithelial monolayers. Am J Physiol1996; 270: 565—573.
17.
Witthoft T. , Eckmann L., Kim JM, Kagnoff MFEnteroinvasive bacteria directly activate expression of iNOS and NO production in human colon epithelial cells. Am J Physiol1998; 275: 564—571.
18.
Gomez-Guerrero C., Lopez-Franco O., Suzuki Y. et al. Nitric oxide production in renal cells by immune complexes: role of kinases and nuclear factor-kappaB. Kidney Int2002; 62: 2022—2034.
19.
Nicolson AG , Haites NE, McKay NG, Wilson HM, MacLeod AM, Benjamin N.Induction of nitric oxide synthase in human mesangial cells. Biochem Biophys Res Commun1993; 193: 1269—1274.
20.
Hirabayashi N., Tanimura H., Yamaue H.Nitrite/nitrate oxide and cytokines changes in patients with surgical stress. Dig Dis Sci2005; 50: 893—897.
21.
Iskit AB, Guc O.Effects of endothelin and nitric oxide on organ injury, mesenteric ischemia, and survival in experimental models of septic shock. Acta Pharmacol Sin2003; 24: 953—957.
22.
Strand OA, Leone A., Giercksky KE, Kirkeboen KANitric oxide indices in human septic shock. Crit Care Med2000; 28: 2779—2785.
23.
Groeneveld AB , Hartemink KJ, de Groot MC, Visser J., Thijs LGCirculating endothelin and nitrate-nitrite relate to hemodynamic and metabolic variables in human septic shock. Shock1999; 11: 160—166.
24.
Kim JM, Kim JS, Jung HC, Song IS, Kim CYUp-regulation of inducible nitric oxide synthase and nitric oxide in Helicobacter pylori-infected human gastric epithelial cells: possible role of interferon-gamma in polarized nitric oxide secretion. Helicobacter2002; 7: 116—128.
25.
Pastor CM, Suter PMEvidence that humans produce less nitric oxide than experimental animals in septic shock. Crit Care Med1998; 26: 1135—1142.
26.
Albina JEOn the expression of nitric oxide synthase by human macrophages. Why no NO? . J Leukoc Biol1995; 58: 643—649.
27.
Busse R., Mulsch A.Induction of nitric oxide by cytokines in vascular smooth muscle cells. FEBS Lett1990; 275: 87—90.
28.
Llorens S., Jordan J., Nava E.The nitric oxide pathway in the cardiovascular system. J PhysiolBiochem2002; 58: 179—188.
29.
Harrison DG , Cai H.Endothelial control of vasomotion and nitric oxide production. Cardiol Clin2003; 21: 289—302.
30.
Grip O., Janciauskiene S., Lindgren S.Macrophages in inflammatory bowel disease. Curr Drug Targets InflammAllergy2003; 2: 155—160.
31.
Linton MF, Fazio S.Macrophages, inflammation, and atherosclerosis. Int J Obes Relat Metab Disord2003; 27: 35—40.
32.
Barthlen W. , Stadler J., Lehn NL, Miethke T., Bartels H., Siewert JRSerum levels of end products of nitric oxide synthesis correlate positively with tumor necrosis factor alpha and negatively with body temperature in patients with postoperative abdominal sepsis. Shock1994; 2: 398—401.
33.
Xiong H., Zhu C., Li F. et al. Inhibition of interleukin-12 p40 transcription and NF-kappa B activation by nitric oxide in murine macrophages and dendritic cells. J Biol Chem2003; 279: 10776—10783.
34.
del Fresno C., Gomez-Garcia L., Caveda L. et al. Nitric oxide activates the expression of IRAK-M via the release of TNF-alpha in human monocytes. Nitric Oxide2004; 10: 213—220.
35.
D'Acquisto F., Maiuri MC, de Cristofaro F., Carnuccio R.Nitric oxide prevents inducible cyclooxygenase expression by inhibiting nuclear factor-kappa B and nuclear factor-interleukin-6 activation. Naunyn Schmiedebergs Arch Pharmacol2001; 364: 157—165.
36.
Brune B., Golkel C., von Knethen A.Cytokine and low-level nitric oxide prestimulation block p53 accumulation and apoptosis of RAW 264.7 macrophages. Biochem Biophys Res Commun1996; 229: 396—401.
37.
von Knethen A., Callsen D., Brune B.NF-kappaB and AP-1 activation by nitric oxide attenuated apoptotic cell death in RAW 264.7 macrophages. Mol Biol Cell1999; 10: 361—372.
38.
Janssens S. , Beyaert R.Functional diversity and regulation of different interleukin- 1 receptor-associated kinase (IRAK) family members. Mol Cell2003; 11: 293—302.
39.
Escoll P., del Fresno C., Garcia L. et al. Rapid up-regulation of IRAK-M expression following a second endotoxin challenge in human monocytes and in monocytes isolated from septic patients. Biochem Biophys Res Commun2003; 311: 465—472.
40.
Kobayashi K. , Hernandez LD, Galan JE, Janeway CA, Medzhitov R., Flavell RAIRAKM is a negative regulator of Toll-like receptor signaling. Cell2002; 110: 191—202.
41.
del Fresno C., Otero K., Gomez-Garcia L. et al. Tumor cells deactivate human monocytes by up-regulating IL-1 receptor associated kinase-M expression via CD44 and TLR4. J Immunol2005; 174: 3032—3040.
42.
Starr R., Willson TA, Viney EM et al. A family of cytokine-inducible inhibitors of signalling. Nature1997; 387: 917—921.
43.
Nicola NA, Greenhalgh CJThe suppressors of cytokine signaling (SOCS) proteins: important feedback inhibitors of cytokine action. Exp Hematol2000; 28: 1105—1112.
44.
Naka T., Tsutsui H., Fujimoto M. et al. SOCS-1/SSI-1-deficient NKT cells participate in severe hepatitis through dysregulated cross-talk inhibition of IFN-gamma and IL-4 signaling in vivo. Immunity2001; 14: 535—545.
45.
Baetz A., Frey M., Heeg K., Dalpke AHSuppressor of cytokine signaling (SOCS) proteins indirectly regulate toll-like receptor signaling in innate immune cells. J Biol Chem2004; 279: 54708—54715.
46.
Kimura A., Naka T., Muta T. et al. Suppressor of cytokine signaling-1 selectively inhibits LPS-induced IL-6 production by regulating JAK-STAT. Proc Natl Acad Sci USA2005; 102: 17089—17094.
47.
Kinjyo I., Hanada T., Inagaki-Ohara K. et al. SOCS 1/JAB is a negative regulator of LPS-induced macrophage activation. Immunity2002; 17: 583—591.
48.
Nakagawa R. , Naka T., Tsutsui H. et al. SOCS-1 participates in negative regulation of LPS responses. Immunity2002; 17: 677—687.
49.
Eigler A., Sinha B., Endres S.Nitric oxide-releasing agents enhance cytokine-induced tumor necrosis factor synthesis in human mononuclear cells. Biochem Biophys Res Commun1993; 196: 494—501.
50.
Kuo HP, Wang CH, Huang KS et al. Nitric oxide modulates interleukin-1beta and tumor necrosis factor-alpha synthesis by alveolar macrophages in pulmonary tuberculosis. Am J Respir Crit Care Med2000; 161: 192—199.
51.
Matata BM, Galinanes M.Peroxynitrite is an essential component of cytokines production mechanism in human monocytes through modulation of nuclear factor-kappaB DNA binding activity. J Biol Chem2002; 277: 2330—2335.
52.
Deakin AM, Payne AN, Whittle Bjr, Moncada S.The modulation of IL-6 and TNF-release by nitric oxide following stimulation of J774 cells with LPS and IFN-gamma. Cytokine1995; 7: 408—416.
53.
Ignaro LJ, Napoli C., Loscalzo J.Nitric oxide donors and cardiovascular agents modulating the bioactivity of nitric oxide, (an overview). Circ Res2002 ; 90: 21—28.
54.
Napoli C., Ignarro LJNitric oxide and artherosclerosis. Nitric Oxide2001; 5: 88—97.
55.
Kojda G., Harrison D.Interaction between NO and reactive oxygen species: pathophysiological importance in atherosclerosis, hypertension, diabetes and heart failure. Cardiovasc Res1999; 43: 562—571.
56.
López-Collazo E., Hortelano S., Boscá L.Interferon-alpha/beta inhibits the apoptosis induced by lipopolysaccharide and interferon-gamma in murine peritoneal macrophages . J Interferon Cytokines Res1998; 18: 461—467.
57.
Boscá L., Hortelano S.Mechanism of nitric oxide-dependent apoptosis: involvement of mitochondrial mediators. Cell Signal1999; 11: 239—244.
58.
Taylor EL, Megson IL, Haslett C., Rossi AGNitric oxide: a key regulator of myeloid inflammatory cell apoptosis. Cell Death Differ2003; 10: 418—430.
59.
Albina JE, Reichner JSRole of nitric oxide in mediation of macrophage cytotoxicity and apoptosis . Cancer Metastasis Rev1998; 17: 39—53.
60.
Schindler H. , Bogdan C.NO as a signaling molecule: effects on kinases . Int Immunopharm2001; 1: 1443—1455.
